Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.34 |
| ▸ | HTR5A | P47898 | 4/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.32 |
| ▸ | OXTR | P30559 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29990044 | 0.94 | CHRM1 (0.34) | TSPOCHRM1HRH1PAK1HTR5A | |
| SCHEMBL21379060 | 0.94 | CHRM1 (0.34) | TSPOCHRM1HRH1PAK1HTR5A | |
| SCHEMBL1495917 | 0.84 | TSPO (0.37) | TSPOHTR5AAVPR1AOXTR | |
| SCHEMBL21397117 | 0.83 | HTR5A (0.39) | CHRM1HRH1PAK1HTR5ANR3C2 | |
| SCHEMBL1495860 | 0.83 | TSPO (0.37) | TSPOCHRM1HRH1HTR5AAVPR1A | |
| SCHEMBL1496015 | 0.81 | TSPO (0.48) | TSPOHTR5AAVPR1AOXTR | |
| Hydrochloric Acid SCHEMBL25255088 | 0.80 | TSPO (0.47) | TSPOHTR5AAVPR1AOXTR | |
| SCHEMBL21379004 | 0.79 | TSPO (0.35) | TSPOHTR5AAVPR1AOXTR | |
| SCHEMBL21379279 | 0.78 | TSPO (0.34) | TSPOCHRM1HRH1HTR5AAVPR1A | |
| SCHEMBL21396613 | 0.78 | AVPR1A (0.37) | TSPOCHRM1AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| EP-2256119-B1 | Vasopressin V1a antagonists | VANTIA LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2292621-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2011-03-09 | — | — | EP | disclosed |
| EP-2264037-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2010-12-22 | — | — | EP | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | AVPR1A, AVPR2, AVPR1B | TSPO 1733/4885CHRM1 1568/4885HRH1 246/4885 |
| US-20090029965-A1 | Vasopressin V1a Antagonists | AVPR1A, AVPR2, AVPR1B | TSPO 1733/4885CHRM1 1568/4885HRH1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.